Nasus Pharma director reports option holdings

Nasus Pharma Ltd director David Silberman filed an initial ownership report showing a stock option position rather than a recent trade.

Rhea-AI Filing Summary

Nasus Pharma Ltd director David Silberman filed an initial ownership report showing a stock option position rather than a recent trade. He holds options to buy 10,000 Ordinary Shares at an exercise price of $5.38 per share, granted on December 11, 2025. The grant vests at 2.0833% of the total each month after that date. As of March 18, 2026, all 10,000 options remain outstanding, with 625 options vested and exercisable, and the options are scheduled to expire on December 11, 2035.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Silberman David

Role Director

Type	Security	Shares	Price	Value
holding	Share Option (right to buy)	--	--	--

Holdings After Transaction: Share Option (right to buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did Nasus Pharma (NSRX) director David Silberman report?

David Silberman reported holding options to purchase 10,000 Nasus Pharma Ordinary Shares. These options represent a right to buy shares at a fixed exercise price, rather than a recent stock trade or sale in the open market.

What are the key terms of David Silberman’s Nasus Pharma (NSRX) stock options?

Silberman’s options cover 10,000 Ordinary Shares with an exercise price of $5.38 per share. They were granted on December 11, 2025 and are scheduled to expire on December 11, 2035, giving a long exercise window.

How do David Silberman’s Nasus Pharma (NSRX) options vest over time?

The options vest at a rate of 2.0833% of the total grant each month following December 11, 2025. This creates gradual monthly vesting rather than a single cliff date, aligning ongoing service with increasing exercisable ownership.

How many of David Silberman’s Nasus Pharma (NSRX) options are currently exercisable?

As of March 18, 2026, Silberman has 10,000 options outstanding, of which 625 options are vested and exercisable. The remaining options are still unvested but continue to vest monthly under the grant’s vesting schedule.

Did David Silberman buy or sell Nasus Pharma (NSRX) shares in this filing?

This report reflects a holding of stock options, not a new purchase or sale of Ordinary Shares. It shows his existing right to buy shares under an option grant, rather than an open-market trade or disposal transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/27/2026 - 08:56 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Silberman David

(Last) (First) (Middle)

P.O. BOX 284

(Street)

TEL-AVIV-YAFO 6100201

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Nasus Pharma Ltd [ NSRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)(1)	03/11/2026	12/11/2035	Ordinary Shares	10,000	$5.38(1)	D

Explanation of Responses:

1. Options to purchase 10,000 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on December 11, 2025, with 2.0833% of the total grant vesting monthly following December 11, 2025. As of March 18, 2026, 10,000 options remain outstanding, of which 625 are vested and exercisable, at an exercise price of $5.38 per share, expiring December 11, 2035.

	/s/ Silberman David	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)